Clinical trial · Observational
Predictive Value of DNA Mismatch Repair System in Colorectal Cancers
Assessment of the DNA Mismatch Repair System is Crucial in Colorectal Cancers Necessitating Adjuvant Treatment: a Propensity Score-matched and Win Ratio Analysis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* Microsatellite instable (MSI) tumors represent almost the 15% of all sporadic colorectal cancers (CRCs). * Literature data show that this unique tumor population appears to be poorly responsive to conventional chemotherapy and conversely reveals excellent results to immunotherapy. * Our data, as demonstrated by propensity score-matched and win ratio analysis, show that there are no substantial differences between MSI and MSS tumors in early CRC stages treated with surgery alone. * On the contrary, stable tumors (MSS) did much better than MSI tumors in advanced CRC stages undergoing conventional adjuvant treatment. * Determination of status of DNA mismatch repair system is crucial in high-risk CRCs to optimize treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| MSI-H Colorectal Cancer | MSI-H Colorectal Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| colorectal resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- group 1 or MSS
- description
- colorectal cancers (CRCs) with stable microsatellite
- interventionNames
- Procedure: colorectal resection
- label
- group 2 or MSI
- description
- colorectal cancers (CRCs) with unstable microsatellite
- interventionNames
- Procedure: colorectal resection
Primary outcomes (1)
- measure
- survival rate
- timeFrame
- "From date of surgical operation until the date of death from any cause assessed up to 60 months"
- description
- overall survival
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 86 Years
Show eligibility criteria text
Inclusion Criteria: * all consecutive CRC patients observed from January 2014 to December 2021 Exclusion Criteria: * Patients with suspected or confirmed Lynch's syndrome (12 patients) and rectal cancers (98 patients) undergoing neoadjuvant treatment
References
Publications (0)
Data not yet available